{
    "hands_on_practices": [
        {
            "introduction": "Modern surgical decision-making for hereditary cancer syndromes begins with an accurate interpretation of genetic data. This exercise places you in a genetics clinic, where you must translate the probabilistic language of American College of Medical Genetics and Genomics (ACMG) variant classifications—pathogenic, likely pathogenic, and variant of uncertain significance—into definitive operative plans for patients with different Multiple Endocrine Neoplasia (MEN) syndromes. This practice is essential for learning when to recommend irreversible prophylactic surgery versus when to pursue surveillance, balancing oncologic risk against intervention-related morbidity .",
            "id": "5154240",
            "problem": "A surgeon in an endocrine genetics clinic receives referrals for patients with suspected Multiple Endocrine Neoplasia (MEN) syndromes after germline testing. The clinic follows the American College of Medical Genetics and Genomics (ACMG) standards, which aggregate diverse evidence (population frequency, computational predictions, segregation, de novo status, functional assays, and established mutational hotspots) into categorical classifications that reflect a posterior probability of pathogenicity for a given variant. Widely accepted frameworks map these categories to probability ranges: “pathogenic” corresponds to a very high posterior probability (for example, greater than $0.99$), “likely pathogenic” to high but not conclusive probability (for example, greater than $0.90$ and less than or equal to $0.99$), and “variant of uncertain significance” (VUS) to intermediate probability (for example, greater than or equal to $0.10$ and less than or equal to $0.90$). In operative endocrinology, irreversible risk-reducing procedures must be justified by sufficiently high certainty of pathogenicity together with disease penetrance, natural history, and proven benefit of intervention.\n\nConsider the following patients and statements about operative decision-making for MEN syndromes under ACMG classification:\n\nA. A 12-year-old with a family history of medullary thyroid carcinoma and a germline rearranged during transfection (*RET*) variant whose aggregated evidence yields a posterior probability of approximately $0.92$ (classified as “likely pathogenic”). It is appropriate to plan prophylactic total thyroidectomy in accordance with syndrome- and codon-specific timing guidance after confirming clinical and family-history concordance and excluding conflicting evidence.\n\nB. A 28-year-old asymptomatic woman with a *RET* VUS detected on a multigene panel after her father developed medullary thyroid carcinoma at age 35. Her basal calcitonin is normal and neck ultrasound is unremarkable. Prophylactic thyroidectomy should be deferred; instead, surveillance and efforts to obtain segregation and functional evidence should proceed, avoiding cascade predictive testing in unaffected relatives based solely on the VUS.\n\nC. A 25-year-old asymptomatic man with a pathogenic *MEN1* variant should undergo immediate subtotal parathyroidectomy to prevent future primary hyperparathyroidism, because pathogenic classification alone is sufficient to justify prophylactic parathyroid surgery in Multiple Endocrine Neoplasia type 1 (MEN1).\n\nD. For a *RET* VUS identified in a kindred with multiple affected relatives, demonstrating co-segregation of the variant with disease across several meioses together with a validated in vitro functional assay showing loss of normal function can justify reclassification to “likely pathogenic,” after which operative plans can be revised accordingly.\n\nE. In an adult with a *RET* VUS, markedly elevated basal calcitonin greater than $100$ pg/mL and highly suspicious nodules on ultrasound, total thyroidectomy is indicated and the VUS serves as an independent surgical indication.\n\nF. A carrier of a “likely pathogenic” variant in cyclin-dependent kinase inhibitor 1B (*CDKN1B*), consistent with Multiple Endocrine Neoplasia type 4 (MEN4), should begin syndrome-appropriate surveillance; irreversible prophylactic endocrine surgery in an asymptomatic carrier is generally not indicated solely on the basis of genotype without phenotypic disease.\n\nWhich of the above statements are most appropriate applications of ACMG variant classifications to operative decision-making in MEN syndromes?\n\nSelect all that apply.",
            "solution": "The problem statement is evaluated as valid. It is scientifically grounded in the principles of clinical genetics, molecular pathology, and surgical endocrinology, specifically concerning Multiple Endocrine Neoplasia (MEN) syndromes and the application of American College of Medical Genetics and Genomics (ACMG) variant classification guidelines. The problem is well-posed, objective, and provides sufficient information to assess the validity of the provided statements. The scenarios described are realistic and present common, albeit complex, challenges in the field.\n\nThe core principles guiding this analysis are:\n1.  Surgical decisions, especially irreversible prophylactic procedures, require a high degree of certainty regarding the pathogenicity of a genetic variant. The threshold for action depends on a risk-benefit analysis that incorporates disease penetrance, disease-specific morbidity/mortality, and the efficacy and morbidity of the proposed intervention.\n2.  ACMG categories represent probabilities of pathogenicity. A \"pathogenic\" variant (e.g., probability $P > 0.99$) is considered sufficient for clinical action in high-penetrance conditions. A \"likely pathogenic\" variant ($0.90  P \\leq 0.99$) represents a high but not definitive risk, requiring careful consideration of corroborating evidence (e.g., family history) and a shared decision-making process. A \"variant of uncertain significance\" (VUS) is, by definition, not actionable for predictive or prophylactic measures; the primary goal is reclassification through further evidence gathering.\n\nBased on these principles, each statement is evaluated as follows:\n\n**A. A 12-year-old with a family history of medullary thyroid carcinoma and a germline rearranged during transfection (*RET*) variant whose aggregated evidence yields a posterior probability of approximately $0.92$ (classified as “likely pathogenic”). It is appropriate to plan prophylactic total thyroidectomy in accordance with syndrome- and codon-specific timing guidance after confirming clinical and family-history concordance and excluding conflicting evidence.**\n\nThis statement concerns a \"likely pathogenic\" variant in the context of MEN type 2 (MEN2), a high-penetrance syndrome where prophylactic thyroidectomy is the standard of care for carriers of pathogenic variants to prevent aggressive medullary thyroid carcinoma (MTC). A posterior probability of $0.92$ indicates a high likelihood of pathogenicity. While not meeting the $0.99$ threshold for \"pathogenic,\" the risk of inaction (developing metastatic MTC) is substantial. The statement correctly qualifies the decision by including essential safeguards:\n-   Adherence to codon-specific risk stratification, as different *RET* mutations confer different levels of risk and dictate the optimal age for surgery.\n-   Confirmation of clinical and family history concordance, ensuring the variant fits the observed disease pattern in the family.\n-   Exclusion of conflicting evidence, which is a critical step in variant interpretation.\nGiven the high penetrance of MTC and the proven benefit of early prophylactic thyroidectomy, acting on a \"likely pathogenic\" variant with these rigorous checks in place represents an appropriate and justifiable clinical judgment, balancing the small residual uncertainty against a very high clinical risk.\n\nVerdict: **Correct**.\n\n**B. A 28-year-old asymptomatic woman with a *RET* VUS detected on a multigene panel after her father developed medullary thyroid carcinoma at age 35. Her basal calcitonin is normal and neck ultrasound is unremarkable. Prophylactic thyroidectomy should be deferred; instead, surveillance and efforts to obtain segregation and functional evidence should proceed, avoiding cascade predictive testing in unaffected relatives based solely on the VUS.**\n\nThis statement describes the standard-of-care management for a VUS. A VUS is non-actionable for irreversible interventions like prophylactic surgery. The probability of pathogenicity is uncertain (by definition, in the range of $0.10$ to $0.90$). Therefore, deferring thyroidectomy is mandatory. The correct course of action is twofold: ($1$) clinical surveillance of the individual (basal calcitonin, neck ultrasound) to monitor for phenotypic expression of the disease, and ($2$) pursuing further evidence to reclassify the VUS. This includes segregation analysis (testing the affected father and other relatives to see if the variant tracks with the disease) and seeking functional data. Crucially, offering predictive testing for a VUS to other at-risk relatives is inappropriate, as a positive result is uninterpretable and cannot be used for clinical management. This statement accurately captures all facets of appropriate VUS management.\n\nVerdict: **Correct**.\n\n**C. A 25-year-old asymptomatic man with a pathogenic *MEN1* variant should undergo immediate subtotal parathyroidectomy to prevent future primary hyperparathyroidism, because pathogenic classification alone is sufficient to justify prophylactic parathyroid surgery in Multiple Endocrine Neoplasia type 1 (MEN1).**\n\nThis statement is flawed in its clinical reasoning. While a pathogenic *MEN1* variant confers a near-$100\\%$ lifetime risk of developing primary hyperparathyroidism (PHPT), prophylactic parathyroidectomy is not the standard of care. Unlike MTC in MEN2, PHPT in MEN1 is typically a more indolent disease that can be effectively monitored with annual biochemical screening (serum calcium and parathyroid hormone). Surgery is indicated based on phenotypic expression—that is, when the patient develops hypercalcemia and meets standard surgical criteria for PHPT. The timing and extent of surgery are complex, but the indication is the presence of disease, not the presence of the genotype alone in an asymptomatic, normocalcemic individual. The claim that pathogenic classification *alone* is sufficient justification is incorrect for parathyroid disease in MEN1.\n\nVerdict: **Incorrect**.\n\n**D. For a *RET* VUS identified in a kindred with multiple affected relatives, demonstrating co-segregation of the variant with disease across several meioses together with a validated in vitro functional assay showing loss of normal function can justify reclassification to “likely pathogenic,” after which operative plans can be revised accordingly.**\n\nThis statement contains a critical scientific error specific to the gene in question. While the general process of using segregation and functional data to reclassify a VUS is correct, the statement specifies that the functional assay should show \"loss of normal function\" for a *RET* variant. This is wrong. *RET* is a proto-oncogene, and its pathogenic role in MEN2 is due to a *gain-of-function* mutation that leads to constitutive activation of its tyrosine kinase activity. A loss-of-function mutation in *RET* causes a different condition (Hirschsprung's disease). Therefore, a functional assay supporting pathogenicity for MEN2 would need to demonstrate a gain, not a loss, of function. Because this detail is fundamentally incorrect, the statement is not an appropriate application of the principle.\n\nVerdict: **Incorrect**.\n\n**E. In an adult with a *RET* VUS, markedly elevated basal calcitonin greater than $100$ pg/mL and highly suspicious nodules on ultrasound, total thyroidectomy is indicated and the VUS serves as an independent surgical indication.**\n\nThis statement contains a critical logical error. A basal calcitonin level greater than $100$ pg/mL, especially with corresponding suspicious nodules on ultrasound, is pathognomonic for MTC. This clinical evidence *on its own* is a definitive indication for total thyroidectomy. The surgery is being performed to treat existing, diagnosed cancer. The *RET* VUS is not the indication for surgery. While the presence of MTC in this patient strongly suggests that their *RET* VUS is, in fact, pathogenic (this clinical finding would be strong evidence, PS4, for reclassification), the VUS itself, as a \"variant of uncertain significance,\" cannot serve as an *independent* surgical indication. The indication is the biochemical and imaging diagnosis of MTC. The statement's claim that the VUS is an independent indication is false.\n\nVerdict: **Incorrect**.\n\n**F. A carrier of a “likely pathogenic” variant in cyclin-dependent kinase inhibitor 1B (*CDKN1B*), consistent with Multiple Endocrine Neoplasia type 4 (MEN4), should begin syndrome-appropriate surveillance; irreversible prophylactic endocrine surgery in an asymptomatic carrier is generally not indicated solely on the basis of genotype without phenotypic disease.**\n\nThis statement correctly addresses the management of a lower-penetrance MEN syndrome. MEN4, caused by mutations in *CDKN1B*, is much rarer and has a significantly lower and more variable penetrance than MEN1 or MEN2. The spectrum of tumors can include pituitary adenomas, PHPT, and neuroendocrine tumors, but the lifetime risk for any specific tumor is not as high as in other MEN syndromes. Given this lower penetrance and less predictable natural history, the risk-benefit analysis does not favor prophylactic organ removal in an asymptomatic carrier. The appropriate management is lifelong surveillance tailored to the spectrum of MEN4-associated tumors, with intervention planned only upon detection of phenotypic disease. This contrasts with the approach in high-penetrance syndromes like MEN2 and correctly states that genotype alone is insufficient for prophylactic surgery in this context.\n\nVerdict: **Correct**.",
            "answer": "$$\\boxed{ABF}$$"
        },
        {
            "introduction": "A key measure of success in oncologic surgery is the clearance of tumor-specific biomarkers from the bloodstream. This problem models the postoperative dynamics of serum calcitonin, the key marker for medullary thyroid carcinoma in MEN2A, following a curative total thyroidectomy. By applying the principles of first-order kinetics, you can calculate the expected time to achieve a biochemical cure, providing a powerful quantitative framework for interpreting postoperative surveillance data and understanding the half-life of tumor products .",
            "id": "5154230",
            "problem": "A patient with Multiple Endocrine Neoplasia type $2$A (MEN$2$A) undergoes total thyroidectomy and appropriate lymphadenectomy for medullary thyroid carcinoma arising from parafollicular C-cells. Preoperative basal serum calcitonin is $1200\\,\\mathrm{pg/mL}$. After complete resection, serum calcitonin elimination follows first-order kinetics in the absence of residual disease, with a known serum half-life of $24$ hours. The clinical laboratory defines “undetectable” calcitonin as less than $2\\,\\mathrm{pg/mL}$.\n\nUsing only the fundamental definition of first-order elimination and the definition of half-life under first-order kinetics, determine the minimum postoperative time at which biochemical cure recognition (calcitonin becoming undetectable) is expected if no residual calcitonin production remains.\n\nExpress your final answer in hours and round to three significant figures.",
            "solution": "The problem statement is first subjected to validation.\n\n**Step 1: Extract Givens**\n- Patient diagnosis: Multiple Endocrine Neoplasia type $2$A (MEN$2$A) with medullary thyroid carcinoma.\n- Procedure: Total thyroidectomy and appropriate lymphadenectomy.\n- Initial condition: Preoperative basal serum calcitonin, $C_0 = 1200\\,\\mathrm{pg/mL}$.\n- Kinetic model: Serum calcitonin elimination follows first-order kinetics.\n- Kinetic parameter: Serum half-life, $t_{1/2} = 24$ hours.\n- Final condition: Undetectable calcitonin level, $C(t)  2\\,\\mathrm{pg/mL}$.\n- Assumption: Complete resection, meaning no residual calcitonin production.\n- Objective: Determine the minimum postoperative time, $t$, at which the calcitonin level becomes undetectable.\n- Required format: The answer must be in hours, rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded**: The problem is scientifically sound. MEN$2$A is a well-characterized genetic syndrome causing medullary thyroid carcinoma (MTC). MTC arises from parafollicular C-cells and secretes calcitonin, which serves as a crucial tumor marker. The treatment described (total thyroidectomy) is standard. Pharmacokinetic modeling using first-order elimination is a standard approach for hormone and drug clearance. The provided values for calcitonin levels and its half-life are within clinically reported ranges.\n- **Well-Posed**: The problem is well-posed. It provides an initial concentration, a final concentration threshold, and a well-defined kinetic model (first-order decay) with its characteristic parameter (half-life). These elements are sufficient to determine a unique time.\n- **Objective**: The problem is stated using precise, objective, and quantitative medical and scientific terms. There is no ambiguity or subjectivity.\n\n**Step 3: Verdict and Action**\nThe problem is valid. It is self-contained, scientifically grounded, and well-posed. A solution will be derived.\n\nThe elimination of serum calcitonin is stated to follow first-order kinetics. The fundamental differential equation describing a first-order process is:\n$$\n\\frac{dC}{dt} = -kC(t)\n$$\nwhere $C(t)$ is the concentration of the substance at time $t$, and $k$ is the first-order rate constant.\n\nIntegrating this differential equation from time $t=0$ to a later time $t$ gives the familiar exponential decay equation:\n$$\nC(t) = C(0) \\exp(-kt)\n$$\nIn this problem, the initial concentration at the time of complete resection ($t=0$) is the preoperative basal level, $C_0 = C(0) = 1200\\,\\mathrm{pg/mL}$.\n\nThe rate constant $k$ is related to the half-life, $t_{1/2}$. By definition, the half-life is the time required for the concentration to decrease to one-half of its initial value. Thus, at $t = t_{1/2}$, we have $C(t_{1/2}) = \\frac{1}{2} C(0)$. Substituting this into the integrated rate law:\n$$\n\\frac{1}{2} C(0) = C(0) \\exp(-k t_{1/2})\n$$\n$$\n\\frac{1}{2} = \\exp(-k t_{1/2})\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k t_{1/2}\n$$\n$$\n-\\ln(2) = -k t_{1/2}\n$$\nSolving for the rate constant $k$:\n$$\nk = \\frac{\\ln(2)}{t_{1/2}}\n$$\nWe are given $t_{1/2} = 24$ hours. We can now express the concentration at any time $t$ in terms of the given parameters:\n$$\nC(t) = C_0 \\exp\\left(-\\frac{\\ln(2)}{t_{1/2}}t\\right)\n$$\nThe problem asks for the minimum time, let's call it $t_{final}$, at which the calcitonin level becomes \"undetectable\", defined as less than $2\\,\\mathrm{pg/mL}$. To find this minimum time, we set the concentration $C(t_{final})$ equal to the threshold value of $2\\,\\mathrm{pg/mL}$.\n$$\nC(t_{final}) = 2\\,\\mathrm{pg/mL}\n$$\nWe now solve for $t_{final}$:\n$$\n2 = 1200 \\exp\\left(-\\frac{\\ln(2)}{24}t_{final}\\right)\n$$\nTo solve for $t_{final}$, we first isolate the exponential term:\n$$\n\\frac{2}{1200} = \\exp\\left(-\\frac{\\ln(2)}{24}t_{final}\\right)\n$$\n$$\n\\frac{1}{600} = \\exp\\left(-\\frac{\\ln(2)}{24}t_{final}\\right)\n$$\nNext, we take the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{600}\\right) = -\\frac{\\ln(2)}{24}t_{final}\n$$\nUsing the property of logarithms $\\ln(1/x) = -\\ln(x)$:\n$$\n-\\ln(600) = -\\frac{\\ln(2)}{24}t_{final}\n$$\nThe negative signs cancel out:\n$$\n\\ln(600) = \\frac{\\ln(2)}{24}t_{final}\n$$\nFinally, we solve for $t_{final}$:\n$$\nt_{final} = \\frac{24 \\ln(600)}{\\ln(2)}\n$$\nNow, we calculate the numerical value.\n$$\nt_{final} \\approx \\frac{24 \\times 6.396929655}{0.6931471806}\n$$\n$$\nt_{final} \\approx \\frac{153.5263117}{0.6931471806}\n$$\n$$\nt_{final} \\approx 221.49506\\,\\text{hours}\n$$\nThe problem requires the answer to be rounded to three significant figures. The first three significant figures are $2$, $2$, and $1$. The fourth digit is $4$, which is less than $5$, so we round down.\n$$\nt_{final} \\approx 221\\,\\text{hours}\n$$\nThis represents the minimum time required for the patient's serum calcitonin to fall to the upper limit of the \"undetectable\" range. Any time greater than this will result in a concentration less than $2\\,\\mathrm{pg/mL}$.",
            "answer": "$$\\boxed{221}$$"
        },
        {
            "introduction": "Effective surgical care extends beyond the operating room to the meticulous management of postoperative complications. This practice addresses one of the most common sequelae of parathyroid surgery in MEN1: postoperative hypocalcemia. You will first use a standard clinical formula to diagnose the true severity of hypocalcemia by correcting for serum albumin levels, and then apply this assessment to calculate the precise infusion rate for intravenous calcium replacement . This is a critical, hands-on skill for ensuring patient safety after complex endocrine procedures.",
            "id": "5154278",
            "problem": "A $52$-year-old patient with Multiple Endocrine Neoplasia type $1$ (MEN1) underwent subtotal parathyroidectomy with autotransplantation for multigland primary hyperparathyroidism. On postoperative day $1$, the patient develops perioral paresthesias and carpopedal spasm. Laboratory values show a measured total serum calcium of $6.4$ mg/dL and serum albumin of $3.0$ g/dL. Serum magnesium is normal. You are asked to initiate intravenous calcium therapy.\n\nUse the clinically validated corrected calcium relation, which adjusts total calcium for albumin binding, given by\n$$\nCa_{\\text{corr}} \\;=\\; Ca_{\\text{meas}} \\;+\\; 0.8\\,(4.0 - \\text{Albumin}) \\quad \\text{mg/dL},\n$$\nto interpret the severity of hypocalcemia in this symptomatic postoperative state and to select an appropriate continuous elemental calcium infusion rate following an evidence-based protocol for symptomatic hypocalcemia after parathyroidectomy in MEN1.\n\nAssume your institution’s protocol for symptomatic hypocalcemia with neuromuscular irritability is to start a continuous infusion of elemental calcium at $1.0$ mg/kg/h. Pharmacy prepares an infusion by adding $10$ ampules of $10\\%$ calcium gluconate, each ampule being $10$ mL and containing $93$ mg of elemental calcium, to dextrose 5% in water (D5W) to a final volume of $1.0$ L. The patient’s weight is $68$ kg.\n\nCompute the required infusion pump rate to deliver the protocol dose. Round your final pump rate to three significant figures and express your answer in mL/h.",
            "solution": "The problem statement is evaluated for validity.\n\nGivens extracted from the problem statement:\n- Patient age: $52$ years\n- Diagnosis: Multiple Endocrine Neoplasia type $1$ (MEN1)\n- Clinical state: Postoperative day $1$ after subtotal parathyroidectomy, presenting with perioral paresthesias and carpopedal spasm.\n- Measured total serum calcium: $Ca_{\\text{meas}} = 6.4$ mg/dL\n- Serum albumin: $\\text{Albumin} = 3.0$ g/dL\n- Serum magnesium: normal\n- Corrected calcium formula: $Ca_{\\text{corr}} = Ca_{\\text{meas}} + 0.8 \\times (4.0 - \\text{Albumin})$\n- Patient weight: $W = 68$ kg\n- Infusion protocol: $1.0$ mg/kg/h of elemental calcium.\n- Infusion preparation: $10$ ampules of $10\\%$ calcium gluconate added to D5W to a final volume $V_{\\text{total}} = 1.0$ L.\n- Elemental calcium per ampule: $93$ mg.\n- Final answer requirement: Round the infusion pump rate to three significant figures, in units of mL/h.\n\nValidation verdict:\nThe problem is valid.\n- It is scientifically grounded in the pathophysiology of postoperative hypocalcemia and its management, a common clinical scenario.\n- The provided formula for corrected calcium is a standard clinical tool (the Payne formula).\n- The symptoms, laboratory values, patient weight, and treatment protocol are realistic and well-defined.\n- The problem is self-contained, with all necessary information provided for a unique solution.\n- There are no contradictions, ambiguities, or factual unsoundness.\n\nThe solution proceeds as follows.\n\nFirst, we interpret the severity of the hypocalcemia using the provided formula for corrected calcium, $Ca_{\\text{corr}}$. This contextualizes the clinical decision to initiate an infusion. The normal reference range for total serum calcium is typically $8.5$ to $10.5$ mg/dL. Since calcium is protein-bound, primarily to albumin, the total measured calcium must be corrected for the patient's albumin level.\nGiven:\n- Measured calcium, $Ca_{\\text{meas}} = 6.4$ mg/dL.\n- Serum albumin, $\\text{Albumin} = 3.0$ g/dL.\nThe corrected calcium is calculated as:\n$$\nCa_{\\text{corr}} = Ca_{\\text{meas}} + 0.8 \\times (4.0 - \\text{Albumin})\n$$\nSubstituting the patient's values:\n$$\nCa_{\\text{corr}} = 6.4 + 0.8 \\times (4.0 - 3.0) = 6.4 + 0.8 \\times (1.0) = 6.4 + 0.8 = 7.2 \\; \\text{mg/dL}\n$$\nA corrected calcium of $7.2$ mg/dL is significantly below the normal range, confirming true hypocalcemia. The presence of neuromuscular irritability (perioral paresthesias, carpopedal spasm) indicates that the hypocalcemia is clinically significant and symptomatic, justifying the initiation of intravenous calcium therapy as per the protocol.\n\nNext, we compute the required infusion pump rate. This involves three steps:\n1.  Determine the target dose rate of elemental calcium for the patient.\n2.  Determine the concentration of elemental calcium in the prepared IV infusion bag.\n3.  Calculate the infusion pump rate required to deliver the target dose.\n\nStep 1: Calculate the target dose rate ($D_R$).\nThe protocol specifies an infusion rate of $1.0$ mg of elemental calcium per kilogram of body weight per hour. The patient's weight ($W$) is $68$ kg.\n$$\nD_R = (1.0 \\; \\text{mg/kg/h}) \\times W = (1.0 \\; \\text{mg/kg/h}) \\times (68 \\; \\text{kg}) = 68 \\; \\text{mg/h}\n$$\nThe patient requires $68$ mg of elemental calcium per hour.\n\nStep 2: Calculate the concentration ($C$) of elemental calcium in the IV bag.\nThe infusion is prepared by adding $10$ ampules, each containing $93$ mg of elemental calcium, to a final volume of $1.0$ L.\nFirst, we find the total mass of elemental calcium ($m_{\\text{Ca}}$) in the bag:\n$$\nm_{\\text{Ca}} = (\\text{number of ampules}) \\times (\\text{mass per ampule}) = 10 \\times 93 \\; \\text{mg} = 930 \\; \\text{mg}\n$$\nThe total volume of the infusion ($V_{\\text{total}}$) is $1.0$ L, which must be converted to milliliters to match the desired units for the pump rate (mL/h).\n$$\nV_{\\text{total}} = 1.0 \\; \\text{L} \\times \\frac{1000 \\; \\text{mL}}{1 \\; \\text{L}} = 1000 \\; \\text{mL}\n$$\nThe concentration ($C$) is the total mass of elemental calcium divided by the total volume:\n$$\nC = \\frac{m_{\\text{Ca}}}{V_{\\text{total}}} = \\frac{930 \\; \\text{mg}}{1000 \\; \\text{mL}} = 0.93 \\; \\text{mg/mL}\n$$\n\nStep 3: Calculate the required infusion pump rate ($R_I$).\nThe pump rate in mL/h is found by dividing the target dose rate (in mg/h) by the concentration of the infusion (in mg/mL).\n$$\nR_I = \\frac{D_R}{C} = \\frac{68 \\; \\text{mg/h}}{0.93 \\; \\text{mg/mL}}\n$$\n$$\nR_I \\approx 73.118279... \\; \\text{mL/h}\n$$\nThe problem requires the final answer to be rounded to three significant figures.\n$$\nR_I \\approx 73.1 \\; \\text{mL/h}\n$$\nThus, the infusion pump should be set to a rate of $73.1$ mL/h to deliver the correct dose of elemental calcium.",
            "answer": "$$\\boxed{73.1}$$"
        }
    ]
}